|drug3707||Web + text smoking cessation intervention Wiki||0.58|
|drug2819||Real iTBS to the dlPFC Wiki||0.58|
|drug2818||Real cTBS to the vmPFC Wiki||0.58|
|D016739||Behavior, Addictive NIH||0.29|
|D002318||Cardiovascular Diseases NIH||0.11|
There are 3 clinical trials
Cigarette smoking constitutes the greatest preventable cause of mortality and morbidity in the US. The most critical period for long term success of smoking cessation appears to be in the first 7 days after the quit date. A metaanalysis of 3 pharmacotherapy trials revealed that abstinence during the first 7 days was the strongest predictor of 6 month outcomes (n=1649; Odds ratio: 1.4, P <0.0001; Ashare et al. 2013). Prodigious relapse rates during this first week of smoking cessation are likely due to behavioral and neurobiological factors that contribute to high cue-associated craving and low executive control over smoking. The long term goal of the research is to develop evidence-based transcranial magnetic stimulation protocols to facilitate abstinence during this critical period.
Description: The effect of real vs. sham iTBS to the left DLPFC vs. real vs. sham cTBS to the left MPFC as a tool to modulate the brain response to cigarette cravings will be assessed by comparing the brain activity in the executive circuit and limbic circuit before and after TMS. Participants will receive an MRI brain scan before their first TMS treatment, and at the end of their 10th days of TMS. At each MRI scan, participants will be subjected to a cigarette craving "cue" task within the scanner where elevated brain activity (BOLD signal) will be measured using an fMRI sequence. During each scan, they will see pictures of cigarette cues, neutral cues, and blurred images. The task is meant to induce craving and see how the brain responds to these craving cues.Measure: Neuroimaging outcomes: changes in drug cue reactivity as specified by changes in BOLD signal Time: Through study completion, an average of 8 weeks
Description: Participants will be asked to choose between two conditions in which varying amounts and delays to behavioral outcomes (e.g., $50 now or $100 later) are presented. We will use magnitudes of $100 and $1000 which are the most thoroughly documented among the literature. Across consecutive choices, the delay to the larger outcome will be titrated until reaching the participant's indifference delay (i.e., the delay at which s/he equally values both options). This indifference delay indexes individual participants' rates of delay discounting. Monetary delay discounting has been documented to be predictive to treatment success for smokers.Measure: Changes in Delayed Discounting Cognitive Behavioral Task Time: Through study completion, an average of 8 weeks
Description: This 10-item questionnaire assesses cigarette craving. Participants will be asked to rate from 1 (strongly disagree) to 100 (strongly agree) their agreement with several statements (e.g., "I have a desire for a cigarette right now," and "Nothing would be better than smoking a cigarette right now."). Factor analyses support two factors: one that reflects a strong desire and intention to smoke and one that reflects relief from negative affect associated with an urgent desire to smoke.Measure: Questionnaire on Smoking Urges administered daily both pre/post TMS to measure craving Time: Through study completion, an average of 8 weeks
Description: The hypothetical purchase task (HPT), a validated measure for cigarette demand, will assess cigarette purchases at various price conditions. Participants will hypothetically purchase quantities of cigarettes to use over a 24-hour period across ascending prices (e.g., $0, 0.12, $0.25, $0.50, $1.00, and $2.00 per cigarette). The HPT has been shown to be predictive of treatment outcomes. It will measure how participants value cigarettes throughout the course of the study visits.Measure: Hypothetical Purchase Task to measure tobacco product value and sensitivity Time: Through study completion, an average of 8 weeks
Description: Changes in cigarette use as detected by quantitative cotinine urine screens collected at visits 1, 6, 10, and all follow-upsMeasure: Biochemical assessment of tobacco use via quantitative urine screens to detect cotenine level Time: Through study completion, an average of 8 weeks
Description: This self-reported tobacco product use interview asks participants to retrospectively estimate the number of tobacco products they've used each day for the past 30 days or since the previous assessment, whichever is fewer.Measure: Self- report assessment of tobacco use through Timeline Follow-Back (TLFB) Interview Time: Through study completion, an average of 8 weeks
Description: Breath CO provides an accurate measure of recent exposure to CO, including from smoking combustible tobacco products (95). The CO measurement will be used to determine recency of smoking.Measure: Biochemical assessment of recent tobacco use via breath Carbon Monoxide (CO) sample Time: Through study completion, an average of 8 weeks
The purpose of this study is to understand how to develop and deliver a better smoking cessation program for lower-income young adult smokers.
Description: Self-reported smoking abstinence and biochemical validation (saliva cotinine)Measure: 30-day point prevalence smoking abstinence Time: Assessed at 3-month follow-up
Description: Confidence to quit within the next month (7days) on 0-10 scaleMeasure: Self-efficacy to quit smoking Time: Assessed at 3-month follow-up
Description: Completing 75% or more of 12 weekly check-insMeasure: Intervention engagement Time: 12 weeks
Description: Self-reported smoking abstinenceMeasure: 7-day point prevalence smoking abstinence Time: Assessed at 3-month follow-up
Description: Number of times intentionally stopped smoking cigarettes for 24 hours or longer because trying to quitMeasure: Number of 24-hour quit attempts Time: Assessed at 3-month follow-up
Description: 4 items pertaining to quit support from the text messagesMeasure: Perceived support to quit smoking Time: Assessed 3-month follow-up
Description: Past 30 (90 day) use of tobacco or nicotine products such as cigars, e-cigarettes, chewing tobacco, and nicotine replacement productsMeasure: Pattern and rate of tobacco/e-cigarette use Time: Assessed at 3-month follow-up
This cohort study will obtain electronic health record (EHR) de-identified data from 21 health systems affiliated with the Cancer Center Cessation Initiative (C3I) network or health systems with large numbers of COVID-19 patients to explore whether smoking status, cancer history, and other risk factors among patients diagnosed with COVID-19 are associated with mortality and/or COVID-19 disease severity/complications. Each site will provide de-identified data from their health system EHR on a monthly basis that includes all patients identified as having COVID-19 at some point in the interval from February 1, 2020, through December 31, 2020.
Description: Death resulting from COVID-19 illness in inpatients vs discharge from hospital (binary outcome)Measure: Mortality due to COVID-19 Time: February 1, 2020, through December 31, 2020
Description: COVID-19 severity as measured by intubation for respiratory support (i.e., patient required intubation during hospitalization) - binary variableMeasure: COVID-19 Severity Time: February 1, 2020, through December 31, 2020
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports